MEDITOR INITIATES TRIAL FOR INTRADIALYTIC HYPOTENSION

A A

Meditor Pharmaceuticals has announced the initiation of a Phase II clinical trial for their proprietary lead development compound MTR 104, a low molecular weight isothiourea derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension.

The trial is for intradialytic hypotension (IDH). This double-blind clinical trial, being conducted under an investigational new drug application (IND), will involve chronic renal failure patients who experience IDH.